

July 2, 2025

## Company Update

☑ Change in Estimates | ☑ Target | ■ Reco

### Change in Estimates

	Current		Previous	
	FY26E	FY27E	FY26E	FY27E
<b>Rating</b>	REDUCE		REDUCE	
<b>Target Price</b>	420		394	
Sales (Rs. m)	80,449	91,858	80,449	91,858
% Chng.	-	-	-	-
EBITDA (Rs. m)	12,211	15,074	12,071	14,934
% Chng.	1.2	0.9	-	-
EPS (Rs.)	12.3	16.8	11.9	16.4
% Chng.	3.1	2.3	-	-

### Key Financials - Consolidated

Y/e Mar	FY24	FY25	FY26E	FY27E
Sales (Rs. m)	63,720	72,710	80,449	91,858
EBITDA (Rs. m)	9,760	10,010	12,211	15,074
Margin (%)	15.3	13.8	15.2	16.4
PAT (Rs. m)	4,160	3,290	4,459	6,086
EPS (Rs.)	11.5	9.1	12.3	16.8
Gr. (%)	(23.6)	(20.9)	35.3	36.5
DPS (Rs.)	0.6	0.5	0.6	0.8
Yield (%)	0.1	0.1	0.1	0.2
RoE (%)	8.1	6.0	7.7	9.6
RoCE (%)	7.2	6.2	6.9	8.1
EV/Sales (x)	3.2	2.9	2.8	2.5
EV/EBITDA (x)	21.1	21.0	18.3	15.0
PE (x)	42.2	53.3	39.4	28.9
P/BV (x)	3.3	3.1	2.9	2.7

### Key Data

ARTI.BO | ARTO IN

52-W High / Low	Rs.767 / Rs.344
Sensex / Nifty	83,697 / 25,542
Market Cap	Rs.176bn / \$ 2,054m
Shares Outstanding	363m
3M Avg. Daily Value	Rs.861.95m

### Shareholding Pattern (%)

Promoter's	42.24
Foreign	6.29
Domestic Institution	19.97
Public & Others	31.48
Promoter Pledge (Rs bn)	-

### Stock Performance (%)

	1M	6M	12M
Absolute	3.2	16.4	(31.3)
Relative	0.5	9.2	(34.7)

### Swarnendu Bhushan

swarnendubhushan@plindia.com | 91-22-66322260

### Saurabh Ahire

saurabhahire@plindia.com | 91-22-66322537

## Volume scaling gradually, but realization impacted

### Quick Pointers:

- Targeting double-digit volume growth in FY26; margins to remain stable YoY
- JV with UPL to commercialize in FY27; gradual ramp-up expected


**Aarti Industries demonstrated a volume growth of 17% in FY25, however realizations across key products remained subdued, resulting in lower margins. For FY26, the management has guided double-digit volume growth and expects margins to remain stable. The Energy segment, which contributed 36% to the company's topline in FY25 and is largely comprised of MMA, saw sequential improvement in export volumes, although pricing pressure persists due to volatility in the gasoline-naphtha spread. Over the past few years, the company has undertaken multiple growth initiatives, including capacity expansions in MMA, Nitro Toluene, and Ethylation, which are expected to ramp up gradually. The company is currently executing four long-term contracts, with volume ramp-up anticipated across most of them. However, there remains uncertainty around the achievability of the previously guided peak annual revenue potential from these contracts. Meanwhile, the ongoing capex for Chloro Toluene and its derivatives is slated to commercialize in FY26. These initiatives, along with efforts on cost optimization, are expected to help bridge the gap between the current EBITDA of Rs10bn and the management's target range of Rs18–22bn within three years. While volume growth remains visible, we believe that continued weakness in realizations will likely impact near-term performance. The stock trades at 29x FY27E P/E. We maintain a Reduce rating, valuing it at 25x FY27E EPS, and arrive at a target price of Rs420.**

- Execution of ongoing long-term contracts:** Visible volume growth is expected across all ongoing long-term contracts. EBITDA for Contract 2, which involves the supply of a specialty chemical intermediate and is not linked to volumes, is largely protected. While the initial peak revenue guidance for this contract was Rs6.5bn annually, it may come down to Rs5bn. Contract 3 is expected to generate annual revenue of Rs800–1,000mn, with potential to scale up to Rs1,250mn at peak. For Contract 4, which involves the supply of an agrochemical intermediate, volumes are expected to reach 80–90% of the contracted value; however, topline may be impacted due to continued pressure on realizations. Contract 5, which includes supply of a niche specialty chemical, has an annual revenue potential of Rs15 bn, of which 70–80% is expected to be realized in FY26. Additionally, the commercial operations of the joint venture with UPL, focused on producing downstream derivatives of amines, are expected to commence in FY27, with a ramp-up phase spread over the following 2–3 years.
- Bridge from Rs10bn to Rs18–22bn EBITDA in 3 years:** The management expects a total EBITDA improvement of Rs8–12bn over the next 3 years, driven by multiple levers. Around Rs2–2.5bn is anticipated to come from cost optimization initiatives, for which the necessary capex has already been

completed. An additional Rs3–4bn is expected to be driven by volume growth and the ramp-up of existing projects. Furthermore, Rs3bn in incremental EBITDA is expected from its new product basket, particularly from Chloro Toluene and its downstream derivatives, which have diverse applications across agrochemicals, dyes, pharmaceuticals, and other specialty segments.

- **Capex Outlook:** For FY26, capex is guided to be around Rs10bn, primarily towards expanding capacity for Chloro Toluene and its downstream derivatives. From FY27 onwards, capex is expected to reduce and will mostly be for regular maintenance.

**Exhibit 1: Gasoline-Naphtha at USD16.2/bbl in May'25**



Source: Company, PL

**Exhibit 2: : Maintain Reduce rating, valuing it at 25x FY27E EPS with TP of Rs420**

Y/e March	FY26E	FY27E
EPS (Rs)	12	17
Target multiple		25
<b>Target Price</b>		<b>420</b>

Source: PL, Company

## Financials

### Income Statement (Rs m)

Y/e Mar	FY24	FY25	FY26E	FY27E
<b>Net Revenues</b>	<b>63,720</b>	<b>72,710</b>	<b>80,449</b>	<b>91,858</b>
YoY gr. (%)	(3.7)	14.1	10.6	14.2
Cost of Goods Sold	38,800	46,550	49,735	55,657
Gross Profit	24,920	26,160	30,714	36,201
Margin (%)	39.1	36.0	38.2	39.4
Employee Cost	4,040	4,220	4,827	5,511
Other Expenses	11,120	11,930	13,676	15,616
<b>EBITDA</b>	<b>9,760</b>	<b>10,010</b>	<b>12,211</b>	<b>15,074</b>
YoY gr. (%)	(10.4)	2.6	22.0	23.4
Margin (%)	15.3	13.8	15.2	16.4
Depreciation and Amortization	3,780	4,340	5,134	5,890
<b>EBIT</b>	<b>5,980</b>	<b>5,670</b>	<b>7,077</b>	<b>9,184</b>
Margin (%)	9.4	7.8	8.8	10.0
Net Interest	2,110	2,750	2,620	3,049
Other Income	80	140	140	140
<b>Profit Before Tax</b>	<b>3,950</b>	<b>3,040</b>	<b>4,597</b>	<b>6,275</b>
Margin (%)	6.2	4.2	5.7	6.8
Total Tax	(210)	(230)	138	188
Effective tax rate (%)	(5.3)	(7.6)	3.0	3.0
<b>Profit after tax</b>	<b>4,160</b>	<b>3,270</b>	<b>4,459</b>	<b>6,086</b>
Minority interest	-	-	-	-
Share Profit from Associate	-	-	-	-
<b>Adjusted PAT</b>	<b>4,160</b>	<b>3,290</b>	<b>4,459</b>	<b>6,086</b>
YoY gr. (%)	(23.7)	(20.9)	35.5	36.5
Margin (%)	6.5	4.5	5.5	6.6
Extra Ord. Income / (Exp)	-	(20)	-	-
<b>Reported PAT</b>	<b>4,160</b>	<b>3,270</b>	<b>4,459</b>	<b>6,086</b>
YoY gr. (%)	(23.7)	(21.4)	36.4	36.5
Margin (%)	6.5	4.5	5.5	6.6
Other Comprehensive Income	-	-	-	-
Total Comprehensive Income	4,160	3,270	4,459	6,086
<b>Equity Shares O/s (m)</b>	<b>362</b>	<b>362</b>	<b>363</b>	<b>363</b>
<b>EPS (Rs)</b>	<b>11.5</b>	<b>9.1</b>	<b>12.3</b>	<b>16.8</b>

Source: Company Data, PL Research

### Balance Sheet Abstract (Rs m)

Y/e Mar	FY24	FY25	FY26E	FY27E
<b>Non-Current Assets</b>				
<b>Gross Block</b>	<b>73,984</b>	<b>85,614</b>	<b>1,03,074</b>	<b>1,13,074</b>
Tangibles	73,965	85,595	1,03,055	1,13,055
Intangibles	19	19	19	19
<b>Acc: Dep / Amortization</b>	<b>18,024</b>	<b>22,364</b>	<b>27,498</b>	<b>33,388</b>
Tangibles	17,944	22,284	27,418	33,308
Intangibles	80	80	80	80
<b>Net fixed assets</b>	<b>56,490</b>	<b>63,760</b>	<b>76,086</b>	<b>80,197</b>
Tangibles	56,551	63,821	76,147	80,257
Intangibles	(61)	(61)	(61)	(61)
Capital Work In Progress	12,300	14,540	6,800	6,800
Goodwill	-	-	-	-
Non-Current Investments	230	480	480	480
Net Deferred tax assets	1,430	2,180	2,180	2,180
Other Non-Current Assets	1,110	1,220	1,220	1,220
<b>Current Assets</b>				
Investments	-	-	-	-
Inventories	11,600	14,540	13,224	15,100
Trade receivables	8,540	7,860	13,224	15,100
Cash & Bank Balance	5,160	2,950	1,016	2,079
Other Current Assets	4,210	3,530	5,315	6,069
<b>Total Assets</b>	<b>1,01,150</b>	<b>1,11,120</b>	<b>1,19,648</b>	<b>1,29,340</b>
<b>Equity</b>				
Equity Share Capital	1,810	1,810	1,813	1,813
Other Equity	51,090	54,240	58,476	64,258
<b>Total Network</b>	<b>52,900</b>	<b>56,050</b>	<b>60,288</b>	<b>66,071</b>
<b>Non-Current Liabilities</b>				
Long Term borrowings	15,240	18,670	23,000	22,000
Provisions	630	150	150	150
Other non current liabilities	1,750	1,590	1,590	1,590
<b>Current Liabilities</b>				
ST Debt / Current of LT Debt	20,400	19,220	26,449	30,200
Trade payables	7,240	12,370	4,408	5,033
Other current liabilities	2,980	3,070	3,762	4,296
<b>Total Equity &amp; Liabilities</b>	<b>1,01,150</b>	<b>1,11,120</b>	<b>1,19,648</b>	<b>1,29,340</b>

Source: Company Data, PL Research

**Cash Flow (Rs m)**

Y/e Mar	FY24	FY25	FY26E	FY27E
PBT	3,950	3,050	4,597	6,275
Add. Depreciation	3,780	4,340	5,134	5,890
Add. Interest	2,110	2,750	2,620	3,049
Less Financial Other Income	80	140	140	140
Add. Other	(110)	(90)	(140)	(140)
Op. profit before WC changes	9,880	10,050	12,211	15,074
Net Changes-WC	3,220	2,310	(13,326)	(3,409)
Direct tax	(860)	70	203	(140)
<b>Net cash from Op. activities</b>	<b>12,240</b>	<b>12,430</b>	<b>(912)</b>	<b>11,525</b>
Capital expenditures	(13,060)	(13,790)	(10,000)	(10,000)
Interest / Dividend Income	71	150	140	140
Others	(710)	(340)	-	-
<b>Net Cash from Invst. activities</b>	<b>(13,699)</b>	<b>(13,980)</b>	<b>(9,860)</b>	<b>(9,860)</b>
Issue of share cap. / premium	-	(100)	3	-
Debt changes	6,950	2,490	11,559	2,751
Dividend paid	(540)	(360)	(223)	(304)
Interest paid	(2,110)	(2,750)	(2,620)	(3,049)
Others	(90)	(20)	1,080	-
<b>Net cash from Fin. activities</b>	<b>4,210</b>	<b>(740)</b>	<b>9,798</b>	<b>(603)</b>
<b>Net change in cash</b>	<b>2,751</b>	<b>(2,290)</b>	<b>(974)</b>	<b>1,062</b>
Free Cash Flow	(1,040)	(1,430)	(10,912)	1,525

Source: Company Data, PL Research

**Key Financial Metrics**

Y/e Mar	FY24	FY25	FY26E	FY27E
<b>Per Share(Rs)</b>				
EPS	11.5	9.1	12.3	16.8
CEPS	21.9	21.1	26.5	33.0
BVPS	146.1	154.8	166.3	182.3
FCF	(2.9)	(4.0)	(30.1)	4.2
DPS	0.6	0.5	0.6	0.8
<b>Return Ratio(%)</b>				
RoCE	7.2	6.2	6.9	8.1
ROIC	7.9	7.0	6.9	7.9
RoE	8.1	6.0	7.7	9.6
<b>Balance Sheet</b>				
Net Debt : Equity (x)	0.6	0.6	0.8	0.8
Net Working Capital (Days)	74	50	100	100
<b>Valuation(x)</b>				
PER	42.2	53.3	39.4	28.9
P/B	3.3	3.1	2.9	2.7
P/CEPS	22.1	23.0	18.3	14.7
EV/EBITDA	21.1	21.0	18.3	15.0
EV/Sales	3.2	2.9	2.8	2.5
Dividend Yield (%)	0.1	0.1	0.1	0.2

Source: Company Data, PL Research


**Quarterly Financials (Rs m)**

Y/e Mar	Q1FY25	Q2FY25	Q3FY25	Q4FY25
<b>Net Revenue</b>	<b>18,550</b>	<b>16,280</b>	<b>18,430</b>	<b>19,490</b>
YoY gr. (%)	31.2	12.0	6.4	9.9
Raw Material Expenses	11,550	10,170	12,290	12,510
Gross Profit	7,000	6,110	6,140	6,980
Margin (%)	37.7	37.5	33.3	35.8
<b>EBITDA</b>	<b>3,060</b>	<b>1,960</b>	<b>2,360</b>	<b>2,680</b>
YoY gr. (%)	51.5	(16.2)	(9.2)	(5.3)
Margin (%)	16.5	12.0	12.8	13.8
Depreciation / Depletion	1,020	1,080	1,110	1,130
<b>EBIT</b>	<b>2,040</b>	<b>880</b>	<b>1,250</b>	<b>1,550</b>
Margin (%)	11.0	5.4	6.8	8.0
Net Interest	640	620	850	640
Other Income	60	50	10	(30)
<b>Profit before Tax</b>	<b>1,460</b>	<b>330</b>	<b>410</b>	<b>880</b>
Margin (%)	7.9	2.0	2.2	4.5
Total Tax	70	(180)	(60)	(70)
Effective tax rate (%)	4.8	(54.5)	(14.6)	(8.0)
<b>Profit after Tax</b>	<b>1,390</b>	<b>510</b>	<b>470</b>	<b>950</b>
Minority interest	-	-	-	-
Share Profit from Associates	-	-	-	-
<b>Adjusted PAT</b>	<b>1,390</b>	<b>510</b>	<b>470</b>	<b>950</b>
YoY gr. (%)	95.8	(44.6)	(62.1)	(28.0)
Margin (%)	7.5	3.1	2.6	4.9
Extra Ord. Income / (Exp)	-	-	-	-
<b>Reported PAT</b>	<b>1,390</b>	<b>510</b>	<b>470</b>	<b>950</b>
YoY gr. (%)	95.8	(44.6)	(62.1)	(28.0)
Margin (%)	7.5	3.1	2.6	4.9
Other Comprehensive Income	10	(30)	(80)	240
<b>Total Comprehensive Income</b>	<b>1,400</b>	<b>480</b>	<b>390</b>	<b>1,190</b>
Avg. Shares O/s (m)	363	363	363	363
<b>EPS (Rs)</b>	<b>3.8</b>	<b>1.4</b>	<b>1.3</b>	<b>2.6</b>

Source: Company Data, PL Research

**Price Chart**

**Recommendation History**



No.	Date	Rating	TP (Rs.)	Share Price (Rs.)
1	09-May-25	Reduce	394	449
2	08-Apr-25	Reduce	330	356
3	04-Feb-25	Reduce	411	453
4	08-Jan-25	Reduce	381	405
5	09-Nov-24	Reduce	411	474
6	05-Oct-24	Reduce	512	551
7	13-Aug-24	Reduce	635	735
8	04-Jul-24	Reduce	634	718

**Analyst Coverage Universe**

Sr. No.	CompanyName	Rating	TP (Rs)	Share Price (Rs)
1	Aarti Industries	Reduce	394	449
2	Bharat Petroleum Corporation	Reduce	267	311
3	Bharti Airtel	Accumulate	1,988	1,834
4	Clean Science and Technology	Hold	1,354	1,329
5	Deepak Nitrite	Reduce	1,799	2,096
6	Fine Organic Industries	BUY	5,440	4,690
7	GAIL (India)	Hold	191	184
8	Gujarat Fluorochemicals	Reduce	3,541	3,988
9	Gujarat Gas	Sell	372	464
10	Gujarat State Petronet	Hold	348	339
11	Hindustan Petroleum Corporation	Sell	321	410
12	Indian Oil Corporation	Reduce	122	143
13	Indraprastha Gas	Sell	150	185
14	Jubilant Ingrevia	Hold	713	682
15	Laxmi Organic Industries	Reduce	172	190
16	Mahanagar Gas	Hold	1,410	1,410
17	Mangalore Refinery & Petrochemicals	Sell	109	129
18	Navin Fluorine International	Accumulate	5,161	4,595
19	NOCIL	Reduce	172	184
20	Oil & Natural Gas Corporation	Accumulate	276	242
21	Oil India	BUY	649	430
22	Petronet LNG	Reduce	292	321
23	Reliance Industries	Accumulate	1,482	1,300
24	SRF	Hold	3,069	2,928
25	Vinati Organics	Accumulate	1,882	1,765

**PL's Recommendation Nomenclature (Absolute Performance)**

<b>Buy</b>	: > 15%
<b>Accumulate</b>	: 5% to 15%
<b>Hold</b>	: +5% to -5%
<b>Reduce</b>	: -5% to -15%
<b>Sell</b>	: < -15%
<b>Not Rated (NR)</b>	: No specific call on the stock
<b>Under Review (IIR)</b>	: Rating likely to change shortly

## **ANALYST CERTIFICATION**

### **(Indian Clients)**

We/I, Mr. Swarnendu Bhushan- IIT, MBA Finance, Mr. Saurabh Ahire- MBA, Passed CFA Level II Research Analysts, authors and the names subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect our views about the subject issuer(s) or securities. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report.

### **(US Clients)**

The research analysts, with respect to each issuer and its securities covered by them in this research report, certify that: All of the views expressed in this research report accurately reflect his or her or their personal views about all of the issuers and their securities; and No part of his or her or their compensation was, is or will be directly related to the specific recommendation or views expressed in this research report.

## **DISCLAIMER**

### **Indian Clients**

Prabhudas Lilladher Pvt. Ltd, Mumbai, India (hereinafter referred to as "PL") is engaged in the business of Stock Broking, Portfolio Manager, Depository Participant and distribution for third party financial products. PL is a subsidiary of Prabhudas Lilladher Advisory Services Pvt Ltd. which has its various subsidiaries engaged in business of commodity broking, investment banking, financial services (margin funding) and distribution of third party financial/other products, details in respect of which are available at [www.plindia.com](http://www.plindia.com).

This document has been prepared by the Research Division of PL and is meant for use by the recipient only as information and is not for circulation. This document is not to be reported or copied or made available to others without prior permission of PL. It should not be considered or taken as an offer to sell or a solicitation to buy or sell any security.

The information contained in this report has been obtained from sources that are considered to be reliable. However, PL has not independently verified the accuracy or completeness of the same. Neither PL nor any of its affiliates, its directors or its employees accepts any responsibility of whatsoever nature for the information, statements and opinion given, made available or expressed herein or for any omission therein.

Recipients of this report should be aware that past performance is not necessarily a guide to future performance and value of investments can go down as well. The suitability or otherwise of any investments will depend upon the recipient's particular circumstances and, in case of doubt, advice should be sought from an independent expert/advisor.

Either PL or its affiliates or its directors or its employees or its representatives or its clients or their relatives may have position(s), make market, act as principal or engage in transactions of securities of companies referred to in this report and they may have used the research material prior to publication.

PL may from time to time solicit or perform investment banking or other services for any company mentioned in this document.

PL is a registered with SEBI under the SEBI (Research Analysts) Regulation, 2014 and having registration number INH000000271.

PL submits that no material disciplinary action has been taken on us by any Regulatory Authority impacting Equity Research Analysis activities.

PL or its research analysts or its associates or his relatives do not have any financial interest in the subject company.

PL or its research analysts or its associates or his relatives do not have actual/beneficial ownership of one per cent or more securities of the subject company at the end of the month immediately preceding the date of publication of the research report.

PL or its research analysts or its associates or his relatives do not have any material conflict of interest at the time of publication of the research report.

PL or its associates might have received compensation from the subject company in the past twelve months.

PL or its associates might have managed or co-managed public offering of securities for the subject company in the past twelve months or mandated by the subject company for any other assignment in the past twelve months.

PL or its associates might have received any compensation for investment banking or merchant banking or brokerage services from the subject company in the past twelve months.

PL or its associates might have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past twelve months

PL or its associates might have received any compensation or other benefits from the subject company or third party in connection with the research report.

PL encourages independence in research report preparation and strives to minimize conflict in preparation of research report. PL or its analysts did not receive any compensation or other benefits from the subject Company or third party in connection with the preparation of the research report. PL or its Research Analysts do not have any material conflict of interest at the time of publication of this report.

It is confirmed that Mr. Swarnendu Bhushan- IIT, MBA Finance, Mr. Saurabh Ahire- MBA, Passed CFA Level II Research Analysts of this report have not received any compensation from the companies mentioned in the report in the preceding twelve months

Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions.

The Research analysts for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

The research analysts for this report has not served as an officer, director or employee of the subject company PL or its research analysts have not engaged in market making activity for the subject company

Our sales people, traders, and other professionals or affiliates may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest.

PL and its associates, their directors and employees may (a) from time to time, have a long or short position in, and buy or sell the securities of the subject company or (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the subject company or act as an advisor or lender/borrower to the subject company or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.

### **US Clients**

This research report is a product of Prabhudas Lilladher Pvt. Ltd., which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of FINRA or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

This report is intended for distribution by Prabhudas Lilladher Pvt. Ltd. only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor.

In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors, Prabhudas Lilladher Pvt. Ltd. has entered into an agreement with a U.S. registered broker-dealer, Marco Polo Securities Inc. ("Marco Polo").

Transactions in securities discussed in this research report should be effected through Marco Polo or another U.S. registered broker dealer.

**Prabhudas Lilladher Pvt. Ltd.**

**3rd Floor, Sadhana House, 570, P. B. Marg, Worli, Mumbai-400 018, India | Tel: (91 22) 6632 2222 Fax: (91 22) 6632 2209**

**[www.plindia.com](http://www.plindia.com)**

July 2, 2025

**AMNISH  
AGGARWAL**

Digitally signed by AMNISH AGGARWAL  
 DN: c=IN, o=Personal, ou=1443,  
 2.5.4.20=1315aa248586e270c42343ee465d51c37bdcac5B  
 6aa8f3e9d48d7, postalCode=400015, st=Maharashtra,  
 email=amish1991@plindia.com, cn=AMNISH AGGARWAL  
 5152c9dbb3a1a45a, c=AMNISH AGGARWAL  
 Date: 2025.07.02 14:43:18 +05'30'